Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  ResApp Health Limited    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 11/26
0.09 AUD   -1.10%
04/05RESAPP HEALTH : Morgans rates RAP as Add
AQ
2019RESAPP HEALTH : 2019 Letter to Shareholders
PU
2017RESAPP HEALTH : Updated Corporate Governance Policies
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Resapp Health : Update on Field Evaluation by Médecins Sans Frontières/Doctors Without Borders

09/14/2017 | 12:44am EST

View printer-friendly version

ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provided an update on the planned field evaluation of ResAppDx by Médecins Sans Frontières/Doctors Without Borders (MSF). Key staff at MSF have reaffirmed their belief in the potential of ResApp's core technology, however after reviewing the issues identified by ResApp in its SMARTCOUGH-C study, and the high cost of keeping the project open, MSF will not proceed with its planned field evaluation of ResAppDx at this point in time. ResApp is currently focused on its restart of the US SMARTCOUGH-C paediatric clinical study this US winter, which includes an array of enhanced procedures and features developed in collaboration with the participating US hospitals. ResApp and MSF will maintain their collaborative relationship and seek opportunities for field testing the technology once issues identified in the SMARTCOUGH-C study have been resolved.

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma, pneumonia and upper respiratory tract infections in adults. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as global aid and humanitarian organisations in the developing world.

For more information on ResApp, visit www.resapphealth.com.au

ResApp Health Limited published this content on 14 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 14 September 2017 04:43:05 UTC.


© Publicnow 2017
All news about RESAPP HEALTH LIMITED
04/05RESAPP HEALTH : Morgans rates RAP as Add
AQ
2019RESAPP HEALTH : 2019 Letter to Shareholders
PU
2017RESAPP HEALTH : Updated Corporate Governance Policies
PU
2017RESAPP HEALTH (ASX : RAP) talks study results and clinical trials
FI
2017RESAPP HEALTH : Update on Field Evaluation by Médecins Sans Frontières/Doctors W..
PU
2017RESAPP HEALTH : Update on Field Evaluation by Medecins Sans Frontieres
PU
2017RESAPP HEALTH : SMARTCOUGH-C Study and Paediatric Clinical Strategy Update
PU
2017RESAPP HEALTH : Appendix 4E - Preliminary Final Report
PU
2017RESAPP HEALTH : Dr Philip Currie Joins ResApp's Scientific Advisory Board
PU
2017RESAPP HEALTH : Dr Philip Currie Joins ResApp's Scientific Advisory Board
PU
More news
Financials
Sales 2021 2,40 M 1,77 M 1,77 M
Net income 2021 -4,90 M -3,61 M -3,61 M
Net cash 2021 3,10 M 2,28 M 2,28 M
P/E ratio 2021 -15,2x
Yield 2021 -
Capitalization 69,0 M 50,7 M 50,8 M
EV / Sales 2021 27,5x
EV / Sales 2022 5,47x
Nbr of Employees -
Free-Float 85,9%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 0,21 AUD
Last Close Price 0,09 AUD
Spread / Highest target 131%
Spread / Average Target 131%
Spread / Lowest Target 131%
EPS Revisions
Managers
NameTitle
Tony Keating Chief Executive Officer, Executive Director & MD
Roger Aston Non-Executive Chairman
Udantha Abeyratne Chief Scientist
Rob Keniger Vice President-Technology
Christopher Ntoumenopoulos Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RESAPP HEALTH LIMITED-63.27%52
ORACLE CORPORATION8.95%173 909
SAP SE-15.24%142 574
SERVICENOW INC.89.34%102 885
INTUIT INC.34.39%93 073
DOCUSIGN, INC.207.49%42 008